Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cerilliant
Dow
Fish and Richardson
McKinsey
Chinese Patent Office
Mallinckrodt
Harvard Business School
Chubb

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,067,472

« Back to Dashboard

Which drugs does patent 8,067,472 protect, and when does it expire?

Patent 8,067,472 protects ZOLINZA and is included in one NDA.

This patent has eighty-six patent family members in twenty-eight countries.
Summary for Patent: 8,067,472
Title:Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Abstract: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s): Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA)
Assignee: Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:12/799,368
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,067,472

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,067,472

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,847,122 Polymorphs of suberoylanilide hydroxamic acid ➤ Sign Up
7,399,787 Methods of treating cancer with HDAC inhibitors ➤ Sign Up
7,148,257 Methods of treating mesothelioma with suberoylanilide hydroxamic acid ➤ Sign Up
7,732,490 Methods of treating cancer ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
Argus Health
Accenture
Covington
Merck
Cipla
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.